Comparative Pharmacology
Head-to-head clinical analysis: GENERLAC versus GLYCOPREP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENERLAC versus GLYCOPREP.
GENERLAC vs GLYCOPREP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. It is metabolized by colonic bacteria to short-chain fatty acids (e.g., lactic, acetic, and formic acids), which osmotically increase intraluminal water content, soften stool, and stimulate peristalsis. In hepatic encephalopathy, the acidic environment reduces intestinal ammonia production and absorption by promoting conversion of NH3 to NH4+.
Glycopyrrolate is a competitive antagonist of acetylcholine at muscarinic receptors, thereby inhibiting the effects of parasympathetic nervous system activation. It does not cross the blood-brain barrier significantly, producing peripheral anticholinergic effects.
10-45 mL orally once daily, adjusted to produce 2-3 soft stools per day. Maximum 60 mL/day.
Adults: 10 units subcutaneously 30 minutes before first meal of the day, then 5 units after each subsequent meal. Total daily dose should not exceed 30 units.
None Documented
None Documented
Not applicable; lactulose is a non-absorbable disaccharide that exerts a local osmotic effect in the colon without systemic absorption. Systemic half-life is not relevant as it does not enter circulation.
Terminal half-life 1.5-2 hours in adults; prolonged in renal impairment (up to 10-12 hours in anuria).
Primarily fecal (≥90%) as unchanged drug via colonic excretion; renal elimination is negligible (<1%).
Primarily renal (90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal <10%.
Category C
Category C
Osmotic Laxative
Osmotic Laxative